We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

71 hedge funds and large institutions have $176M invested in Aurinia Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

872% more capital invested

Capital invested by funds: $18.1M → $176M (+$158M)

767% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 6

184% more funds holding

Funds holding: 25 → 71 (+46)

160% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 5

8.39% more ownership

Funds ownership: 21.72% → 30.11% (+8.4%)

35% less call options, than puts

Call options by funds: $6.29M | Put options by funds: $9.66M

Holders
71
Holders Change
+46
Holders Change %
+184%
% of All Funds
1.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
52
Increased
13
Reduced
5
Closed
6
Calls
$6.29M
Puts
$9.66M
Net Calls
-$3.37M
Net Calls Change
-$4M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$27M
2
O
OrbiMed
New York
+$8.3M
3
Franklin Resources
Franklin Resources
California
+$5.77M
4
GPP
Great Point Partners
Connecticut
+$4.62M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.65M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$4.29M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.28M
3
ACP
Acuta Capital Partners
California
-$2.77M
4
AFM
Anson Funds Management
Texas
-$1.65M
5
SG Americas Securities
SG Americas Securities
New York
-$784K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
26
Redmile Group
California
$1.03M +$478K +103,500 +282%
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$915K +$541K +117,200 +1,563%
CS
28
Candriam SCA
Luxembourg
$866K +$545K +118,000 New
UBS Group
29
UBS Group
Switzerland
$824K +$61.9K +13,405 +14%
Renaissance Technologies
30
Renaissance Technologies
New York
$776K +$488K +105,700 New
VKH
31
Virtu KCG Holdings
New York
$770K +$427K +92,465 +741%
IIM
32
Ironwood Investment Management
Massachusetts
$754K +$475K +102,730 New
Millennium Management
33
Millennium Management
New York
$703K +$116K +25,065 +35%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$595K +$374K +81,019 New
IHM
35
Iguana Healthcare Management
New York
$551K +$346K +75,000 New
HP
36
Hikari Power
Japan
$440K +$277K +60,000 New
NIT
37
NumerixS Investment Technologies
British Columbia, Canada
$401K +$252K +54,655 New
Group One Trading
38
Group One Trading
Illinois
$389K +$245K +53,051 New
Parallax Volatility Advisers
39
Parallax Volatility Advisers
California
$367K -$34.3K -7,426 -13%
KAM
40
Kazazian Asset Management
Florida
$330K +$208K +45,000 New
RFCA
41
R&F Capital Advisors
New York
$313K +$197K +42,576 New
ARTA
42
A.R.T. Advisors
New York
$289K +$182K +39,400 New
Deutsche Bank
43
Deutsche Bank
Germany
$281K +$175K +37,800 +6,300%
QT
44
Quantbot Technologies
New York
$275K +$173K +37,554 New
RJFSA
45
Raymond James Financial Services Advisors
Florida
$260K +$164K +35,400 New
AFM
46
Anson Funds Management
Texas
$250K -$1.65M -358,108 -92%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$241K +$152K +32,887 New
TSS
48
Two Sigma Securities
New York
$240K +$151K +32,652 New
LPL Financial
49
LPL Financial
California
$209K +$139K +30,002 New
CG
50
Cutler Group
California
$201K +$122K +26,440 +2,644%
1
2
3 4

AUPH Hedge Fund Activity: Q1 2017 in Review

71 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2017, worth a combined $176M — up 872% from $18.1M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AUPH positions and 6 closed out — a net gain of 46 holders — while 13 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $27M. The largest seller was Goldman Sachs, cutting an estimated $4.29M.

  • 71 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2017, up from 25 in Q4 2016.
  • Funds reported $176M of Aurinia Pharmaceuticals stock for Q1 2017, up 872% quarter-over-quarter.
  • 52 funds opened new Aurinia Pharmaceuticals positions in Q1 2017 and 6 closed out, a net change of +46 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q1 2017 was Fidelity Investments, an estimated $27M added.
  • The largest Aurinia Pharmaceuticals seller in Q1 2017 was Goldman Sachs, an estimated $4.29M sold.

Based on aggregated 13F filings for Q1 2017.